

Treatment of hepatitis C mono-infection in adults – Dutch national guidelines

M.H. Lamers¹, M.M.T.J. Broekman¹, C.A. Boucher², J.T. Brouwer³, D.M. Burger⁴, B. van Hoek⁵, A.I.M. Hoepelman⁶, R.J. de Knegt⁷, H.W. Reesink⁸, J.P.H. Drenth^{1,*}

The first two authors contributed equally to this work

On behalf of The Netherlands Association of Hepato-gastroenterologists, the Netherlands Association of Internal Medicine, and The Dutch Association for the Study of Liver Disease

¹Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, the Netherlands, ²Department of Virology, Erasmus Medical Center Rotterdam, the Netherlands, ³Department of Internal Medicine, Gastroenterology and Hepatology, Reinier de Graaf Group, Delft, the Netherlands, ⁴Department of Pharmacy, Radboud University Nijmegen Medical Center, the Netherlands, ⁵Department of Gastroenterology and Hepatology, Leiden University Medical Center, the Netherlands, ⁶Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, the Netherlands, ⁷Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, the Netherlands, ⁸Department of Gastroenterology and Hepatology, Academic Medical Center Amsterdam, the Netherlands, *corresponding author tel.: +31 (0)24 3614760; fax: +31 (0)24 3540103, e-mail: joostphdrenth@cs.com

ABSTRACT

In this new Dutch guideline for hepatitis C virus infection we provide recommendations for the management of hepatitis C infection. Until 2012 the standard for treatment consisted of pegylated interferon alpha (peg-IFN α) and ribavirin. The advent of first-generation direct antiviral agents such as boceprevir and telaprevir has changed the concept of treatment of adult chronic hepatitis C genotype 1 infected patients.

There are three benefits of boceprevir and telaprevir. They increase the likelihood of cure in 1) naive genotype 1 patients and 2) in patients who did not respond to earlier treatment with peg-IFN α and ribavirin, while 3) allowing shortening of treatment duration from 48 weeks to 24 or 28 weeks, which is possible in 40-60% of non-cirrhotic naive (boceprevir and telaprevir) and relapsing patients (telaprevir).

The use of boceprevir and telaprevir is associated with multiple side effects and awareness of these side effects is needed to guide the patient through the treatment process. This guideline, formulated on behalf of The Netherlands Association of Hepato-gastroenterologists, The Netherlands Association of Internal Medicine, and The Dutch Association for the Study of Liver Disease, serves as a manual for physicians for the management and treatment of acute and chronic hepatitis C virus mono-infection in adults.

KEYWORDS

Boceprevir, hepatitis C, guidelines, pegylated interferon, protease inhibitor, ribavirin, telaprevir

INTRODUCTION

Hepatitis C virus (HCV) infection resulting in chronic liver disease is highly prevalent in Europe.¹ With the introduction of interferon therapy, later combined with ribavirin, eradication of HCV infection became a reality. The last innovation in this field came a decade ago with the introduction of pegylated interferon alpha (peg-IFN α). Further advances in the therapy of HCV infection were in the most part restricted to refinements of the existing dual therapy with peg-IFN α and ribavirin (combination abbreviated to PR).

The watershed in the field came with the clinical introduction of two direct-acting antiviral agents (DAAs) boceprevir (Victrelis[®]) and telaprevir (Incivo[®]). From 2012 these two DAAs were allowed on the market in the Netherlands and are reimbursed by the health insurance companies for the treatment of chronic HCV genotype 1 infection in adults with compensated liver disease (including cirrhosis). Phase 3 studies, including more than 2700 patients, have documented the high antiviral potency of these agents against HCV genotype 1.²⁻⁶ Accordingly,

the treatment of chronic HCV genotype 1 infected patients has changed and led to the introduction of new national guidelines in several countries, and an update of the EASL and AASLD guidelines.⁷⁻⁹ The last Dutch guideline on the treatment of HCV infection stems from 2008.¹⁰ In order to guide the clinician through the changed therapeutic environment we provide the reader with a completely revised guideline with concise recommendations for the management and treatment of HCV mono-infection in adults. For the complete guideline we refer to www.mdl.nl.

BACKGROUND

The clinical progression of chronic HCV infection varies among patients. Some have only minimal structural hepatic changes even after prolonged infection, while others rapidly develop complications such as cirrhosis and hepatocellular carcinoma (HCC).^{11,12} The progression of histological deterioration is independent of HCV genotype and the concentration of HCV RNA in plasma (viral load), but is related to host factors such as gender, obesity, presence of concomitant liver disease, lifestyle aspects (e.g. alcohol use), and the existence of an untreated co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).¹³⁻¹⁵ The overall mortality is increased due to cirrhosis and HCC, but also due to an increased risk of extrahepatic manifestations such as cardiovascular and renal diseases.^{16,17} In contrast, curing HCV infection with antiviral therapy diminishes the risk of cirrhosis and HCC and consequently improves survival compared with patients with persistent viraemia.^{18,19}

There are at least six distinct HCV genotypes. In the Netherlands, ~50% of chronic hepatitis C is caused by genotype 1a and 1b, ~30% by genotype 3, whereas genotype 2 and 4 both account for ~10% of chronic HCV infected patients. Genotype 5 and 6 are uncommon in the Netherlands.^{20,21}

The primary goal of therapy is to eliminate HCV infection which is defined as undetectable plasma HCV RNA 24 weeks after termination of treatment defined as sustained virological response (SVR) (see *table 1* for abbreviations). With PR given for 24 or 48 weeks, SVR can be achieved in 40-60% of HCV genotype 1 or 4 infected patients and in 70-80% of patients infected with HCV genotype 2 or 3.^{9,22,23}

NATURAL HISTORY

In Europe, the incidence of acute HCV infection is around 1 per 100,000 persons per year. This probably underestimates the true incidence because acute HCV infection is asymptomatic in approximately 80% of cases.⁹ After infection, formation of HCV antibodies can take

Table 1. Treatment responses

Category	Characteristics
Rapid viral response (RVR)	HCV RNA undetectable at week 4
Extended rapid viral response (eRVR)	HCV RNA undetectable at week 4 and week 12
Early viral response (EVR)	HCV RNA undetectable at week 12 or a decrease by >2 log
Delayed viral response (DVR)	HCV RNA >2 log decrease but detectable at week 12, undetectable at week 24
End of treatment response (ETR)	HCV RNA undetectable at end of treatment
Sustained viral response (SVR)	HCV RNA undetectable after 24 weeks of follow-up

months, which implies that plasma HCV RNA analysis should be used to diagnose acute HCV infection.²⁴

Spontaneous clearance of HCV infection occurs in 20-30%. Spontaneous clearance is unlikely to happen 12 weeks after infection and treatment should subsequently be initiated to prevent development of chronic HCV infection.^{25,26}

Persistence of plasma HCV RNA for more than six months constitutes a chronic HCV infection. It is thought that chronic hepatitis C affects ~3% of the world population, i.e. 170 million individuals.²⁷ The prevalence in the Netherlands varies between 0.1-0.4%.^{28,29} European prevalence rates are higher (0.4-4%).³⁰ Chronic hepatitis C progresses slowly, over a time frame of 15-50 years. Cohort studies suggest that 10-20% of all infected patients will eventually develop end-stage liver disease, typically after two to three decades.^{12,31} In cirrhotic patients, the annual rate of HCC is 1-4% and chronic hepatitis C induced HCC accounts for one-third of all HCCs.¹¹

INITIAL EVALUATION

As of 2012 treatment of hepatitis C in the Netherlands is preferably restricted to one of the 40 certified and specialised viral hepatitis treatment centres.³²

The initial evaluation of a chronic hepatitis C patient consists of a detailed medical history evaluation, which includes assessment of the source of the HCV infection, presence of current or past alcohol abuse, and use of concomitant medication. Evaluation includes physical examination with special attention to signs of chronic liver disease, cirrhosis and liver failure (e.g. spider nevi, palmar erythema, gynaecomastia, ascites). Laboratory tests should include a full blood count, liver enzymes and function, thyroid and kidney function, and plasma HCV RNA and genotype.¹⁰ Current guidelines recommend vaccination against hepatitis A and hepatitis B for those who are seronegative.^{9,33}

Pretreatment assessment of liver fibrosis or cirrhosis can be important as this may influence indication, strategy and success of treatment.^{9,11,34} Abdominal ultrasound, liver biopsy or elastography are therefore part of the work-up. Liver biopsy remains the golden standard for fibrosis assessment. Non-invasive tests such as transient elastography (FibroScan®) or the use of biomarkers may be useful to identify or exclude cirrhosis. However, the ability of FibroScan® to discriminate between fibrosis stage F1 and F3 is limited.^{35,36}

Positive predictors of SVR with PR therapy can be classified as pretreatment or on-treatment factors. In general, the most important positive pretreatment predictors for SVR are: response to previous PR-based treatment, e.g. naive patients and patients who relapsed to previous therapy respond better than partial and null responders (see table 2 for classification of patient categories), interleukin (IL) 28B CC polymorphism (exclusively HCV genotype 1), and low stage of fibrosis. Other predictors are low baseline viral load (<600,000 IU/ml), genotype non-1, non-HIV co-infection, age under 40 years, and non-black race.³⁷⁻³⁹ The most important on-treatment positive predictive factor for achieving SVR is attaining a rapid viral response (RVR) (see table 1).^{40,41} Other known on-treatment factors are decline in haemoglobin concentrations during PR therapy in hepatitis C genotype 1, ribavirin plasma concentrations and treatment adherence.⁴²⁻⁴⁴ With the use of DAAs, the predictive value of IL28B polymorphism is limited.⁴⁵ In addition, DAAs are more effective in genotype 1b than in genotype 1a patients.^{3,4,46} On-treatment laboratory testing should occur regularly and should include HCV RNA (at the selected time points), haemoglobin, total leucocytes, neutrophils, thrombocytes, and liver enzymes.

INDICATIONS AND CONTRAINDICATIONS FOR ANTIVIRAL THERAPY

Treatment should be considered in all patients who do not have contraindications, especially in those with METAVIR F3 and F4 and should be strongly considered in patients with METAVIR F2 fibrosis. In patients with METAVIR ≥F2 alternatively, therapy can be postponed until more DAAs have become available, allowing interferon-free regimens. There are subgroups with limited benefits from chronic hepatitis C treatment. First, elderly patients (age >70 years) or patients with (longstanding) asymptomatic disease and a low stage of fibrosis (METAVIR ≤F2).⁴⁷ Second, absolute contraindications (such as decompensated cirrhosis or uncontrolled depression, psychosis, epilepsy, pregnancy or planning to become pregnant, and other severe medical diseases) and relative contraindications (such as thrombocytopenia <90 x 10⁹/l, neutrophil count

Table 2. Treatment categories according to the host response during previous treatment

Category	Characteristics
Naive patients	No previous treatment
Relapsers	HCV undetectable at end of treatment, but detectable after 24 weeks of follow-up
Partial responders	>2 log HCV RNA decline at week 12, but detectable HCV RNA at week 24
Null responders	<2 log HCV RNA decline at week 12
Non-responders	Null response or partial response
Viral breakthrough	Detectable HCV RNA at any time during treatment after previous undetectable HCV RNA during antiviral therapy

<1.5 x 10⁹/l, anaemia (haemoglobin <8 mmol/l), renal insufficiency (GFR <30 ml/min), or ongoing alcohol or drug abuse) may preclude therapy. In patients with relative contraindications benefits of treatment should be balanced carefully against the increased risk of side effects.^{9,48} Patients with concomitant HIV or HBV infection or other liver diseases and those with contraindications listed above, were excluded from the phase 3 studies with boceprevir or telaprevir. As a consequence, treatment strategies formulated below cannot be applied to these patients. Finally, patients with virological failure on boceprevir or telaprevir therapy create a cohort of non-responders. Given the extensive cross-resistance that can develop in patients failing either boceprevir or telaprevir, retreatment with the other drug is not advisable. If treatment is postponed, patients should be monitored yearly. Cirrhotic patients should be subjected to abdominal ultrasound for HCC screening once or twice a year.⁴⁹

ANTIVIRAL THERAPY

Acute hepatitis C

Patients with acute HCV monoinfection should be treated if HCV RNA is still positive three months after exposure, because spontaneous clearance is unlikely to happen at this stage.^{26,50} Therapy consists of peg-IFNα monotherapy (peg-IFNα-2a: 180 µg/week, peg-IFNα-2b: 1.5 µg/kg/week) for the duration of 24 weeks. With peg-IFNα monotherapy, SVR rates are more than 90%. The addition of ribavirin has no proven benefit.^{26,51}

Acute HCV infection is frequently reported in HIV co-infected male homosexual patients and for management the reader is referred to appropriate guidelines.^{52,53}

Chronic hepatitis C

Patients with HCV genotype 1

Both boceprevir and telaprevir can only be used in combination with PR for treatment of adult chronic HCV genotype 1 infected patients with compensated liver

disease. Peg-IFN α and ribavirin dosage instructions are either peg-IFN α -2a 180 μ g/week in combination with ribavirin 1000 mg (<75 kg) or 1200 mg (\geq 75 kg) per day or peg-IFN α -2b 1.5 μ g/kg/week in combination with ribavirin 800-1400 mg (<65 kg: 800 mg, 65-80 kg: 1000 mg, 81-105 kg: 1200 mg, and >105 kg: 1400 mg). Both peg-IFN α 2a or 2b, can be prescribed with either boceprevir or telaprevir.^{54,55} Boceprevir should be taken orally three times a day with eight hour intervals. Telaprevir can be taken two (1125 mg) or three (750 mg) times a day, with 12 and 8 hours intervals, respectively. Telaprevir should be taken with food (preferably containing at least 20 gram of fat) and boceprevir with a small meal to increase bioavailability.^{56,57} There are no head-to-head studies that compare boceprevir and telaprevir, which makes it difficult to compare their relative efficacy.^{58,59} SVR rates are assumed to be comparable for both DAAs. The main differences are related to the side-effect profiles, the use of a four-week lead-in period with boceprevir, and the duration of DAA treatment.

With the new DAAs SVR rates have increased to 65-75% in treatment naive patients.^{2,4,60} Some 70-90% of patients who relapsed after PR treatment achieved SVR with boceprevir or telaprevir triple therapy compared with 25-30% in PR control arms. Partial responders obtained SVR in 40-60% with triple therapy compared with 7-15% with PR alone. Null responders achieved SVR in about 30% with telaprevir therapy in combination with PR, compared with 5% treated with PR alone (figure 1 and 2).^{5,6}

A significant proportion of naive patients (44-65%) in phase 3 studies with boceprevir or telaprevir in combination with PR met the criteria for response-guided therapy (RGT) and can be treated for a shorter period (see 'Treatment strategies'). Success rates are very high in these patients (>90%).^{2,4} The main advantages of RGT are that it allows shortening of treatment and prevents unnecessary exposure to side effects.⁶¹

Figure 1. SVR rates in treatment naive patients with HCV genotype 1





Figure 2. SVR rates in treatment experienced patients with HCV genotype 1



Treatment strategies

Depending on the host response during previous treatment and the presence of cirrhosis, the optimal treatment strategy for both DAAs follows from figure 3 and 4. Important considerations about the implementation of these strategies are described here. First, regarding the rules for discontinuation, alternative time points and tolerated levels of viral load are used in DAA regimens. Second, the concept of RGT is dissimilar with respect to its duration and eligibility of patients. RGT can be applied for non-cirrhotic treatment naive patients (boceprevir and telaprevir) and previous relapsers (telaprevir).^{2,4,62} In these cases, duration of treatment can be limited to 24 weeks (telaprevir) or 28 weeks (boceprevir) (figure 3 and 4). Accurate quantitative and qualitative plasma HCV RNA measurement is crucial for choosing the right treatment strategy as this is the indicator for treatment success.²⁻⁶ There are several test characteristics that need to be fulfilled: a lower limit of quantification of 25 IU/ml and a lower limit of detection of 10-15 IU/ml are mandatory in the DAA era. In this respect, RGT can only be applied when HCV RNA is undetectable at selected time points.^{56,57} It is important that a 'detectable but below the limit of quantification' HCV RNA result does not equal an 'undetectable' HCV RNA result.⁶³ A small proportion of naive chronic HCV genotype 1 patients with an RVR and favourable prognostic factors (low viral load <600,000 IU/ml, \geq F2 fibrosis, IL28B CC genotype) do not have added benefit from DAAs and can be treated with PR protecting them from DAA side effects.⁶⁴ If RVR is not achieved, introduction of boceprevir at week 4 is recommended.² On the other hand, retreatment with DAAs in cirrhotic null responders should carefully be discussed considering the low SVR rates (~14%), the lack of alternatives, and likelihood of adverse events.⁶⁵

Figure 3. Boceprevir treatment strategies





Figure 4. Telaprevir treatment strategies



Patients with HCV genotype 2 and 3

Boceprevir and telaprevir are not registered for the treatment of chronic HCV genotype 2 and 3 infected patients.⁶⁶ Current treatment is 24 weeks of peg-IFN α -2a 180 μ g/week or peg-IFN α -2b 1.5 μ g/kg/week with ribavirin 800 mg a day. If there are baseline factors associated with a poor response, ribavirin should be dosed based weight.⁹ SVR rates are around 70-80% in these patients.^{9,67} In case of intolerance for peg-IFN α dosage can be adjusted (peg-IFN α -2a 135 μ g/week or peg-IFN α -2b 1.0 μ g/kg/week) without compromising SVR rates. Sixteen weeks of treatment with peg-IFN α and weight-based ribavirin can be applied to patients with an RVR who cannot complete 24 weeks of treatment because of severe side effects. This strategy is only applicable for patients with favourable baseline factors. However, with shortened therapy there is a slightly increased risk of viral relapse in genotype 3 patients.^{64,68,69} In patients with chronic HCV genotype 2 and 3 infection without an RVR and concomitant advanced liver fibrosis

or cirrhosis or failure on previous treatment, a 48-week treatment strategy may be followed.^{34,67}

Patients with HCV genotype 4, 5 and 6

For genotype 4, 5 and 6 current PR consists of 48 weeks of peg-IFN α with weight-based ribavirin (see section 'antiviral therapy of HCV genotype 1 infection' for peg-IFN α and ribavirin dosage). SVR rates range from 43-70%.⁷⁰ Naive genotype 4 patients with positive prognostic factors (\geq F2 fibrosis, low baseline viral load and an RVR) are eligible for shortened therapy of 24 weeks.^{71,72}

VIRAL RESISTANCE

Both boceprevir and telaprevir are highly specific inhibitors of the viral NS3/4A serine protease. The nucleoside sequence of the NS3/4A protease varies among HCV genotypes. As a result, the antiviral activity of the protease inhibitors differs between the HCV genotypes. Both DAAs were specifically designed for HCV genotype 1 and have limited activity against other genotypes.^{66,73,74} The high mutation rate results in a large diversity in the viral population, which may lead to the selection of protease inhibitor cross-resistant variants, resulting in treatment failure. Therefore, neither of these DAAs can be used as monotherapy and can only be prescribed in combination with PR to prevent the emergence of viral resistant strains.⁷⁵⁻⁷⁷

DRUG-DRUG INTERACTIONS

Boceprevir and telaprevir are substrates for CYP3A and P-glycoprotein (PgP).^{56,57} Compared with boceprevir, telaprevir is a stronger inhibitor of CYP3A and PgP. Drug interactions can be expected when one of both DAAs is used in combination with other drugs which are also CYP3A or PgP inhibitors or inducers enhancing the risk of drug toxicity or a decreased efficacy of the involved drugs. Because of the somewhat different profiles, interactions may vary between the two agents. Therefore, information and advice cannot be implemented equally for both boceprevir and telaprevir. Before starting treatment with DAA-combination therapy, we recommend to check for all possible interactions on <http://www.hep-druginteractions.org/>, the Dutch handbook for drug interactions with anti-HCV infection agents, and/or consult a pharmacist.^{78,79} Some practical examples: the use of boceprevir and telaprevir leads to impaired efficacy of oral oestrogen containing contraceptives, due to low oestrogen concentrations. Therefore, the use of two nonhormonal containing contraceptives is recommended during and at least two months after cessation of boceprevir or

telaprevir.^{80,81} Also, the use of both DAAs with simvastatin should be avoided as concomitant use results in increased drug levels of simvastatin, putting the patient at risk for rhabdomyolysis.^{82,83} Furthermore, drug levels of escitalopram, a frequently used selective serotonin reuptake inhibitor (SSRI), are lowered during boceprevir and telaprevir usage.⁸³

Supplementary file 1 summarises the most important interactions that should be avoided or interactions that require caution. If information on possible interactions is lacking, consider temporary discontinuation of the drug.

SIDE EFFECTS

PR treatment is frequently accompanied by side effects, such as flu-like symptoms, anaemia, neutropenia, thrombocytopenia, and depression. These side effects influence quality of life and may result in dosage reduction or premature treatment discontinuation. This can be prevented by close monitoring and management of side effects.^{42,84}

With the addition of boceprevir and telaprevir to PR new side effects have emerged while other side effects may be aggravated.⁸⁵ For example, rash and (anal) pruritus affects ~50% of patients taking telaprevir while dysgeusia occurs in 40% of patients treated with boceprevir.²⁻⁶ The most important side effects and their management strategies are discussed below.

Anaemia

Phase 3 trials have clearly shown that PR with boceprevir, but especially with telaprevir, results in a higher frequency of anaemia than PR alone.²⁻⁶ Ribavirin dose reduction in patients treated with boceprevir or telaprevir does not compromise efficacy and is the first step of choice.^{86,87} Ribavirin should be reduced by 200 mg per step. During treatment ribavirin can be up-titrated again when haemoglobin levels are acceptable (≥ 7.0 mmol/l). Dose reduction of ribavirin as opposed to dose maintenance supported by erythropoietin in patients with triple therapy is equally effective in terms of achieving SVR.⁸⁸ If used, erythropoietin agents should be discontinued when haemoglobin reaches the threshold of 7.5 mmol/l.⁸⁹ Blood transfusion should be saved for exceptional cases. For patients treated with PR (e.g. non genotype 1 patients), dose reduction should be postponed as long as possible as this negatively influences the chance of SVR.⁴² When interference is necessary, ribavirin or peg-IFN α dose reduction, use of erythropoietin agents or blood transfusions can be considered. No recommendation can be given for the preferred strategy.

Neutropenia

The incidence of neutropenia is higher in patients treated with PR in combination with a DAA. Although there

is little evidence that neutropenia puts the patient at risk for an infection, current recommendations stipulate peg-IFN α reduction when the neutrophil count falls below $0.75 \times 10^9/l$. Furthermore, (temporary) discontinuation of peg-IFN α should be performed when the neutrophil count drops further ($<0.5 \times 10^9/l$).^{9,90} There is no room for granulocyte colony-stimulating factor because of unclear benefit and high costs.⁹¹

Thrombocytopenia

Thrombocytopenia $<90 \times 10^9/l$ is a relative contraindication for treatment of chronic HCV infection.^{9,92} Peg-IFN α reduction is recommended when the platelet count drops below $50 \times 10^9/l$ and should be discontinued when the platelet count falls below $25 \times 10^9/l$. When the platelet count increases again, peg-IFN α can be restarted at a reduced dose.⁹

Rash management

Rash is a common side effect of PR and occurs even more frequently with telaprevir. Moreover, 4-7% of patients in phase 3 trials assigned to telaprevir had to discontinue all antiviral therapy due to dermatological side effects.^{3,4,6} It develops typically on the trunk, extremities and friction sites, it is generally mild by nature and can be treated with local cooling ointment (unguentum emolliens) or with local corticosteroid therapy (class 3) and antihistamines. Patients with rash grade 2 to 4 need to be referred to a dermatologist without delay.⁹³ Severe rash (grade 3) is defined as involvement of more than 50% of body surface or if systemic symptoms occur (fever, lymphadenopathy, arthralgia, or a rise in creatinine or ALAT). In this case, telaprevir has to be discontinued and if there is no improvement within one week, PR also needs to be discontinued.⁹⁴ Generally, the rash will disappear within a couple of weeks after stopping telaprevir. Rare events with telaprevir are the drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). All treatment should be stopped immediately, a dermatologist should be consulted immediately, and glucocorticoids should be considered.⁹⁴

Psychiatric side effects

Psychiatric side effects such as depression, agitation, irritability, insomnia, lack of concentration and emotional instability put the patient at risk for PR dose reduction, lower treatment adherence and premature treatment cessation resulting in lower SVR rates.^{42,95} Prophylactic treatment with an SSRI should be considered in all patients with a history of depression or signs of depression at baseline.⁹⁶ Apart from pretreatment evaluation of feasibility of treatment and possible drug interactions, consider consulting a psychiatrist and/or a specialist in addiction medicine to ensure safety and drug compliance.

FOLLOW-UP AFTER ANTIVIRAL THERAPY

HCV RNA should be tested 24 weeks after the end of treatment. If HCV RNA is negative, SVR is achieved and the patient can be considered to be cured from chronic HCV infection with only a minimal risk of viral recurrence.⁹⁷ Recent data suggest that negative HCV RNA 12 weeks post-treatment is probably sufficient to confirm SVR, although this needs further evaluation.⁹⁸

Hypothyroidism can arise during but also after termination of treatment. Consequently, thyroid function should also be assessed during the first two years after treatment.⁸⁴ Cirrhotic patients should be followed-up, preferably in a specialised Dutch viral hepatitis centre, because they still remain at risk for cirrhosis-related complications. As per the guidelines, abdominal ultrasound has been advised in the follow-up of these patients to screen for HCC and endoscopic assessment for oesophageal varices.^{49,99}

THE FUTURE

With the introduction of boceprevir and telaprevir the development of novel DAAs and immune modulatory therapy with less side effects than peg-IFN α does not stop. There is intense interest for novel agents that avoid the use of peg-IFN α . Indeed, several HCV polymerase inhibitors are in advanced stages of clinical development. Without doubt therapeutic options will expand to other genotypes. In addition, efforts to design better options for difficult to treat patients [for example with HBV or HIV coinfections] will be necessary.

Furthermore, a new group of DAA non-responders will emerge. How and when these patients will be eligible for anti-HCV infection therapy is uncertain. Consequently, these patients will probably be excluded from upcoming trials with second-generation DAAs, which means that at this time, treatment options for this group are limited.

CONFLICTS OF INTEREST

Drs. M.H. Lamers: none

Drs. M.M.T.J. Broekman: none

Prof. Dr. D.M. Burger: received research grants, honoraria for advisory boards and speakers fees from Merck and Tibotec/Janssen

Prof. Dr. A.I.M. Hoepelman: received grants from Roche, Gilead, Merck, and ViiV healthcare and is an advisor for Gilead, Merck, ViiV Healthcare, and Janssen

Dr. R.J. de Knegt: received research grants from BMS, Roche, GlaxoSmithKline, and Janssen, honoraria for

advisory boards and speakers fees from Merck, Janssen, Abbott, Gilead, and Roche

Dr. H.W. Reesink: advisor for Roche Molecular Diagnostics, Anadys, Merck, Arrows, Janssen and Gilead; consults for PRA International, Tibotec, GlaxoSmithKline, Chiron Novartis, and Roche Therapeutics, and received grant and research support from Janssen, Schering-Plough, Merck, Gilead, BMS, PRA International, and Roche

Prof. Dr. B. van Hoek: member of the advisory board for Janssen, Merck, Roche, and Novartis

Prof. Dr. C.A. Boucher: His employer the Erasmus Medical Center, Erasmus University has received research grants from Merck and Roche, consultancy fees from Merck, and travel support from Janssen and Gilead

Dr. J.T. Brouwer: member of the advisory board from Merck

Prof. Dr. J.P.H. Drenth: received grant support from Ipsen, Novartis, Falk, Shire, and Tramedico

On behalf of The Netherlands Association of Hepato-gastroenterologists (NVMDL), The Netherlands Association of Internal Medicine (NIV), and The Dutch Association for the Study of Liver Disease (NVH): C.A. Boucher, J.T. Brouwer, D.M. Burger, B. van Hoek, A.I.M. Hoepelman, R.J. de Knegt, H.W. Reesink, J.P.H. Drenth.

REFERENCES

1. Lavanchy D. The global burden of hepatitis C. *Liver Int.* 2009;29 Suppl 1:74-81.
2. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med.* 2011;364:1195-206.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med.* 2011;364:2405-16.
4. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med.* 2011;365:1014-24.
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. *New Engl J Med.* 2011;364:1207-17.
6. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for Retreatment of HCV Infection. *New Engl J Med.* 2011;364:2417-28.
7. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology.* 2011;54:1433-44.
8. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. *Aliment Pharmacol Ther.* 2012;35:647-62.
9. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol.* 2011;55:245-64.
10. de Bruijne J, Buster EH, Gelderblom HC, et al. Treatment of chronic hepatitis C virus infection – Dutch national guidelines. *Neth J Med.* 2008;66:311-22.
11. Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med.* 2001;345:41-52.

12. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). *Liver Int.* 2009;29 Suppl 1:89-99.
13. Williams MJ, Lang-Lenton M. Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. *J Viral Hepat.* 2011;18:17-22.
14. Poynard T, Ratziv V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. *J Hepatol.* 2001;34:730-9.
15. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. *Clin Infect Dis.* 2004;39:1507-13.
16. Lee MH, Yang HI, Lu SN, et al. Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study. *J Infect Dis.* 2012;206:469-77.
17. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. *Dig Liver Dis.* 2007;39:2-17.
18. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. *Clin Gastroenterol Hepatol.* 2011;9:509-16 e1.
19. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. *Clin Gastroenterol Hepatol.* 2010;8:280-8.
20. van Soest H, Boland GJ, van Erpecum KJ. Hepatitis C: changing genotype distribution with important implications for patient management. *Neth J Med.* 2006;64:96-9.
21. de Vries MJ, te Rijdt B, van Nieuwkerk CM. Genotype distribution amongst hepatitis C patients in The Netherlands. *Neth J Med.* 2006;64:109-13.
22. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. *N Engl J Med.* 2009;361:580-93.
23. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. *Hepatology.* 2010;51:1176-84.
24. Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. *J Hepatol.* 2005;42 Suppl(1):S108-14.
25. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology.* 2003;125:80-8.
26. Deterding K, Grüner, N., Buggisch, P, et al. Early versus delayed treatment of acute hepatitis C: final results of the randomized controlled german hep-net acute HCV-III study. *J Hepatol.* 2012;56:S21.
27. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis.* 2005;5:558-67.
28. Slavenburg S, Verduyn-Lunel FM, Hermsen JT, Melchers WJ, te Morsche RH, Drenth JP. Prevalence of hepatitis C in the general population in the Netherlands. *Neth J Med.* 2008;66:13-7.
29. Vriend HJ, Op de Coul EL, van de Laar TJ, Urbanus AT, van der Klis FR, Boot HJ. Hepatitis C virus seroprevalence in The Netherlands. *Eur J Public Health.* 2012.
30. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. *J Hepatol.* 2008;48:148-62.
31. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology.* 2008;48:418-31.
32. http://www.mdl.nl/hepatitis_behandelcentra/ / www.NIV.nl.
33. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. *Aliment Pharmacol Ther.* 2004;19:715-27.
34. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and Safety of Peginterferon Alfa-2a (40kD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis. *Hepatology.* 2010;51:388-97.
35. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). *J Hepatol.* 2010;53:1013-21.
36. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. *Aliment Pharmacol Ther.* 2009;30:557-76.
37. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. *N Engl J Med.* 2004;350:2265-71.
38. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature.* 2009;461:399-401.
39. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology.* 2003;37:600-9.
40. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)/ribavirin. *J Hepatol.* 2005;43:425-33.
41. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. *J Hepatol.* 2011;55:69-75.
42. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology.* 2002;123:1061-9.
43. Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. *Gastroenterology.* 2010;139:1602-11.
44. Loustaud-Ratti V, Carrier P, Rousseau A, et al. Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. *Dig Liver Dis.* 2011;43:850-5.
45. Thompson AJ, McHutchison JG. Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus? *Hepatology.* 2012;56:373-81.
46. Poordad F, Bronowicki JP, Gordon SC, et al. Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. *Gastroenterology.* 2012. Epub 2012/05/26.
47. Niederau C, Huppe D, Zehnter E, et al. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. *World J Gastroenterol.* 2012;18:1339-47.
48. McGowan CE, Fried MW. Barriers to hepatitis C treatment. *Liver Int.* 2012;32 Suppl 1:151-6.
49. Guideline Hepatocellular Carcinoma (HCC) (in concept). Available at: www.oncoline.nl. Comprehensive Cancer Centre the Netherlands (IKNL). Viewed on [6 November 2012].
50. National Institute for Public Health and Environment: Dutch national guideline needlestick injuries. April 2007.
51. Wiegand J, Deterding K, Cornberg M, Wedemeyer H. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. *J Antimicrob Chemother.* 2008;62:860-5.
52. Arends JE, Lambers FA, van der Meer JT, et al. Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. *Neth J Med.* 2011;69:43-9.
53. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. *AIDS.* 2011;25:399-409.
54. Marcellin P, Forns X, Goester T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. *Gastroenterology.* 2011;140:459-68 e1; quiz e14.
55. Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. *Clin Gastroenterol Hepatol.* 2013;11:81-7 e4; quiz e5.
56. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf. Product information Incivo® (telaprevir) tablets.
57. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002332/WC500109786.pdf. Product information Victrelis® (boceprevir) capsules.

58. Cooper CL, Druyts E, Thorlund K, et al. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. *Therapeutics Clin Risk Manage.* 2012;8:105-30.
59. Cure S, Diels J, Gavart S, Bianic F, Jones E. Efficacy of telaprevir and boceprevir in treatment-naive and treatment-experienced genotype 1 chronic hepatitis C patients : an indirect comparison using Bayesian network meta-analysis. *Curr Med Res Opin.* 2012.
60. Aronson SJ, de Bruijne J, Schinkel J, Weegink CJ, van der Valk M, Reesink HW. [New class of medicines for chronic hepatitis C]. *Ned Tijdschr Geneesk.* 2012;156(10):A3840. Epub 2012/03/08. Nieuwe klasse medicijnen voor chronische hepatitis C.
61. Reddy KR, Lin F, Zoulim F. Response-guided and -unguided treatment of chronic hepatitis C. *Liver Int.* 2012;32 Suppl 1:64-73.
62. Liu J, Jadhav PR, Amur S, et al. Response Guided Telaprevir Therapy in Prior Relapsers?: The Role of Bridging Data from Treatment-Naive and Experienced Subjects. *Hepatology.* 2012. Epub 2012/04/11.
63. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. *Hepatology.* 2012;55:1048-57.
64. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. *Hepatology.* 2011;54:789-800.
65. Pol S, Roberts SK, Andreone P, et al. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the realize phase III study. *Hepatology.* 2011;54:375A.
66. Mangia A, Mottola L. Treatment of non-genotype 1 hepatitis C virus patients. *Curr Gastroenterol Rep.* 2012;14:87-93.
67. Hadziyannis SJ, Sette H Jr., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med.* 2004;140:346-55.
68. Mangia A, Mottola L. What's new in HCV genotype 2 treatment. *Liver Int.* 2012;32 Suppl 1:135-40.
69. Manns M, Zeuzem S, Sood A, et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. *J Hepatol.* 2011;55:554-63.
70. Khatib MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. *J Hepatol.* 2011;54:1250-62.
71. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology.* 2007;46:1732-40.
72. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology.* 2008;135:451-8.
73. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. *Gastroenterology.* 2006;131:997-1002.
74. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. *Gastroenterology.* 2007;132:1270-8.
75. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. *Gastroenterology.* 2007;132:1767-77.
76. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. *Gastroenterology.* 2010;138:447-62.
77. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. *Hepatology.* 2009;50:1709-18.
78. Burger DM. Drug interactions with anti-HCV-agents. 2012; an update of the table and more information can be found at www.knmp.nl and enter HCV as search term.
79. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. *J Hepatol.* 2012. Epub 2012/11/10.
80. Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N. The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir. *J Clin Pharmacol.* 2011. Epub 2011/11/01.
81. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. *Ann Hepatol.* 2012;11:179-85.
82. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. *Antimicrob Agents Chemother.* 2011;55:4569-74.
83. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. *Hepatology.* 2012;55:1620-8.
84. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. *Gut.* 2006;55:1350-9.
85. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. *Liver Int.* 2012;32 Suppl 1:32-8.
86. Manns MP, Markova AA, Serrano BC, Cornberg M. Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1. *Liver Int.* 2012;32 Suppl 1:27-31.
87. Sulkowski MS, Roberts S, N. Afdhal, P, et al. Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies. *J Hepatol.* 2012;56(Suppl 2):S459-S60.
88. Poordad FF, Lawitz EJ, Reddy KR, et al. A Randomized Trial Comparing Ribavirin Dose Reduction Versus Erythropoietin for Anemia Management in Previously Untreated Patients with Chronic Hepatitis C Receiving Boceprevir Plus Peginterferon/Ribavirin. *J Hepatol.* 2012;56:S559-S.
89. Lippi G, Franchini M, Falavolo EJ. Thrombotic complications of erythropoiesis-stimulating agents. *Semin Thromb Hemost.* 2010;36:337-49.
90. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. *Hepatology.* 2010;52:1225-31.
91. Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation. *J Viral Hepat.* 2011;18:e381-93.
92. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. *J Hepatol.* 2010;53:455-9.
93. Picard O, Cacoub P. Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. *Clin Res Hepatol Gastroenterol.* 2012. Epub 2012/04/10.
94. Cacoub P, Bourliere M, Lubbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. *J Hepatol.* 2012;56:455-63.
95. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. *Psychiatry Res.* 2001;105:45-55.
96. Sulkowski MS, Cooper C, Hunyady B. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. *Nat Rev Gastroenterol Hepatol.* 2011;8:212-23.
97. Trapero-Marugan M, Mendoza J, Chaparro M, et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. *World J Gastroenterol.* 2011;17:493-8.
98. Martinot-Peignoux M, Stern C, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. *Hepatology.* 2010;51:1122-6.
99. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. *Liver Int.* 2007;27:186-91.